2026 Half Year Report: A Strong First Half for entX

During the six months ended 30 June 2026, entX continued to build the infrastructure, manufacturing capability and industry relationships supporting the development and commercialisation of its nuclear science and engineering technologies.

Medical Isotopes

A key focus during the period was the continued development of entX’s medical isotope capabilities.

Progress at the Advanced Radiation Manufacturing Facility (ARMF) in Adelaide is supporting the Company’s plans to establish domestic production capability for medical isotopes. The facility is being developed to support the production, processing and purification of radioisotopes for applications including radiopharmaceutical development.

entX is also continuing to develop its broader isotope supply chain and commercial relationships, with commercial thorium-228 production targeted for the first quarter of 2027.

Space & Defence

entX continued to advance its technologies for potential applications in space and defence.

The Company’s GenX betavoltaic technology progressed with the commissioning of its prototype manufacturing facility in Adelaide. The facility is designed to support the production and testing of GenX devices and the development of customer prototypes.

entX also continued development of its Radioisotope Heater Unit (RHU), which is designed to provide long-duration heat for applications where conventional power and heating systems may be unsuitable.

The RHU programme progressed towards a planned sub-orbital demonstration, with flight readiness activities continuing during the period.

Future Technologies

Alongside its Medical Isotopes and Space & Defence programmes, entX continued to develop its broader portfolio of nuclear science and engineering technologies.

The Company’s approach is focused on progressing technologies from development and prototyping through to commercial application, supported by collaboration with industry, research organisations and customers.

Looking Ahead

The first half of 2026 was focused on building the capability and infrastructure required to support the next stage of entX’s technology portfolio.

As the Company moves into the second half of the financial year and beyond, priorities include progressing isotope production capability, advancing GenX and RHU development, and continuing engagement with customers and industry partners.

Watch the 2026 Half Year Summary below for an overview of the Company’s progress.

The complete entX Limited 2026 Half Year Report is available to read below.